Use Permitted Sample Clauses

The 'Use Permitted' clause defines the specific ways in which a party is allowed to use certain assets, information, or services provided under an agreement. Typically, this clause outlines the scope of authorized activities, such as using software for internal business operations or accessing data solely for evaluation purposes. By clearly delineating what is and is not permitted, the clause helps prevent misuse, unauthorized distribution, or exploitation of the subject matter, thereby protecting the interests of the party granting the rights.
Use Permitted. Individuals performing services (physical or logical) or having unescorted access within the Company Space (defined below), will meet the following individual eligibility requirements for access to U.S. Government Controlled Unclassified Information or Technology1, and Non-Controlled Unclassified Government Contract-related Information (collectively, “Sensitive Government Data”): (a) Supplier will only use individuals who are resident citizens of the United States, and have an active U.S. Government Public Trust background investigation of NAC-I, which has been adjudicated and approved through the respective U.S. Government Central Adjudication Facility (“CAF”) Authority (collectively, “U.S. Resources”). (b) Individuals, who do not meet the definition of a U.S. Resource, may have limited access to the Company Space provided that those individuals are escorted and under constant supervision by a U.S. Resource, and are effectively precluded from access to Sensitive Government Data. This requirement does not apply to Medical, Police, Fire or other emergency responders’, when responding in an official capacity within the Company Space. When requested, these officials will be afforded access to all areas of the Company Space through key or access control. Company will be notified immediately, when these situations occur. Notwithstanding the foregoing, Supplier Personnel who are not U.S. Resources may access the Company Space via the Company-provided fail-over switch in any event in which life, health or safety is threatened as determined by Supplier in its reasonable discretion (an “Emergency Event”); provided that Supplier will notify Company promptly of any Emergency Event and following any Emergency Event, Supplier will make available to Company at the Service Location the Supplier Personnel who accessed the Company Space and will cause such Supplier Personnel to execute any non-disclosure agreement, in form and substance satisfactory to Supplier in its reasonable discretion, as may be required by Company. Unless otherwise agreed to in writing by Company, Supplier agrees to allow only those personnel who are eligible to work in the United States to have access to Company Space. All Supplier Personnel performing Services that requires access to Company Space will be fully qualified to perform the tasks assigned them. Supplier will provide Company with such information regarding proposed Supplier Personnel to be assigned to perform Services as Company may reas...
View SourceView Similar (8)
Use Permitted. Individuals performing services (physical or logical) or having unescorted access within the Company Space, will meet the following individual eligibility requirements for access to U.S. Government Classified Information or Technology2: Supplier will only use individuals who are resident citizens of the United States, and have an active U.S. Government security clearance investigation of NACLC/SECRET, which can be verified through the Joint Personnel Adjudication System (collectively, “Cleared Resource”). Individuals who do not meet the definition of a Cleared Resource, and who are resident citizens of the United States, may have limited access to the Company Space provided that those individuals are escorted and under constant supervision by a Cleared Resource, and are effectively precluded from access to Classified Information or Technology. Resident Aliens (“Permanent Resident”) and Non-Resident Aliens (“Visa Holder” or “Work Authorizations”) will not perform services (whether physical or logical) and will not have access (whether escorted or unescorted), except as expressly agreed in writing in advance by Company and approved by the Company Corporate Facility Security Officer. This requirement does not apply to Medical, Police, Fire or other emergency responders’, when responding in an official capacity within the Company Space. When requested, these officials will be afforded access to all areas of the Company Space through key or access control. Company will be notified immediately, when these situations occur. Notwithstanding the foregoing, Supplier Personnel who are not Cleared Resources may access the Company Space via the Company-provided fail over switch in any Emergency Event; provided that Supplier will notify Company within twenty-four hours of any Emergency Event and following any Emergency Event, Supplier will 1 Controlled Unclassified Information or Technology, the export of which is controlled by the International Traffic in Arms Regulations (“ITAR”) or the Export Administrative Regulations (“EAR”). The export of technical data, which is inherently military in nature, is controlled by the ITAR. The export of technical data, which has both military and commercial uses, is controlled by the EAR. Controlled Unclassified Information includes other forms information or technology that is (i) pertinent to the national interests of the United States or to the important interests of entities outside the Federal Government, and (ii) under law or p...
View SourceView Similar (2)
Use Permitted. For the operation of a discount variety store and for any other lawful purpose or purposes; provided, however, that Tenant shall not use the Demised Premises for any prohibited use as set forth in Exhibit D attached hereto.
View Source
Use Permitted. To TAG's knowledge, current local zoning ------------- ordinances, general plans and other applicable land use regulations and all private covenants, conditions and restrictions, if any, affecting the Properties, permit the transfer of the Properties and the use of the Properties for its current use (and reconstruction and resumption of use in the event of damage, destruction, or cessation of use) as a matter of right for an unlimited time period and not merely as a legal non-conforming use.
View Source
Use Permitted. The use of the Property for the purposes for which it is now used is not precluded by any restrictive covenant or provision, legislation or order.
View Source
Use Permitted. The reproduction of INFORMATION is not permitted unless authorized in writing by the party supplying the information. 2.1. The parties shall make all reasonable efforts to keep confidential information and / or any knowledge that can be shared by examination or writing them. 2.2. The parties will restrict the disclosure of information a their employees based on the need to know them and inform these employees of the mentioned condition, through confidentiality agreement term. 2.3. If, in the marketing effort TECHNOLOGY, the INFORMATION have to be disclosed to third parties other than employees of the Parties, such action shall be subject to prior written approval of the other party, but the disclosure will not be made unless the third party to take such obligation to safeguard iNFORMATION just as the stipulated in this NDA. 2.4. The Parties recognize that not restructure engineer, disassemble, or otherwise desunirão examine the physical construction of any INFORMATION.
View Source
Use Permitted. Current local zoning ordinances, general plans and ------------- other applicable land use regulations and all private covenants, conditions and restrictions, if any, affecting the Property, permit the transfer of the Property and the use of the Property for its current use (and reconstruction and resumption of use in the event of damage, destruction, or cessation of use) as a matter of right for an unlimited time period and not merely as a legal non-conforming use.
View Source
Use Permitted. LICENSEE shall use best effort to cause the network to afford credits to the City. The City acknowledges and agrees that the aforementioned credit and trademark notice, including size, style, and placement thereof, shall be at LICENSEE’s and the network’s sole discretion. Any inadvertent failure to include such credit shall not be a material breach of this Agreement so long as LICENSEE takes reasonable action to cure the same on a prospective basis.
View Source

Related to Use Permitted

  • Compliance with Law; Permits (a) Except with respect to Gaming Laws, the Company and its Subsidiaries are in compliance with, and are not in default under or in violation of, any applicable federal, state, local or foreign law, statute, ordinance, rule, regulation, judgment, order, injunction, decree or agency requirement of any Governmental Entity (collectively, “Laws” and each, a “Law”), except where such non-compliance, default or violation have not had or would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. The Company and each of its Subsidiaries are in compliance with all Gaming Laws applicable to them or by which any of their respective properties are bound, except where any non-compliance would not be material to the Company and its Subsidiaries, taken as a whole. Since January 1, 2012, neither the Company nor any of its Subsidiaries has received any written notice or, to the knowledge of the Company, other communication from any Governmental Entity regarding any violation of, or failure to comply with, any Law, except where such violation or failure has not had or would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. (b) The Company and its Subsidiaries are in possession of all material franchises, grants, authorizations, licenses, permits, easements, variances, exceptions, consents, certificates, approvals, clearances, permissions, qualifications and registrations and orders of all applicable Governmental Entities, and all rights under any Company Material Contract with all Governmental Entities, and have filed all tariffs, reports, notices and other documents with all Governmental Entities necessary for the Company and its Subsidiaries to own, lease and operate their properties and assets and to carry on their businesses as they are now being conducted (the “Company Permits”), except where the failure to possess or file the Company Permits has not had or would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. Except as has not had or would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, all Company Permits are in all respects valid and in full force and effect and are not subject to any administrative or judicial proceeding that would reasonably be expected to result in modification, termination or revocation thereof. Company and each of its Subsidiaries is in material compliance with the terms and requirements of all Company Permits, except where such noncompliance has not had or would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect.

  • Compliance with Laws; Permits (a) (i) Each of the Company and its Subsidiaries is and, since the Lookback Date has been, in compliance with all Laws and Orders applicable to the conduct of the Company and its Subsidiaries and (ii) since the Lookback Date, none of the Company or its Subsidiaries has received any written or oral notice from any Governmental Entity or any other person alleging a material violation of or noncompliance with any such Laws or Orders, except, in the case of each of the foregoing clauses (i) and (ii), as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. (b) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, each of the Company and its Subsidiaries holds all permits, licenses, registrations, approvals, consents, accreditations, waivers, exemptions, certificates and authorizations of any Governmental Entity required for the ownership and use of its assets and properties or the conduct of its business (including for the occupation and use of the Company Leased Real Property) (collectively, “Company Permits”) and is in compliance with all terms and conditions of such Company Permits. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, all of such Company Permits are valid and in full force and effect and none of such Company Permits will be terminated as a result of, or in connection with, the consummation of the transactions contemplated hereby. None of the Company or its Subsidiaries is in default under any such Company Permit and no condition exists that, with the giving of notice or lapse of time or both, would constitute a default under such Company Permit, and no Proceeding is pending or, to the Knowledge of the Company, threatened, to suspend, revoke, withdraw, modify or limit any such Company Permit in a manner that has had or would reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect.

  • Compliance; Permits All activity undertaken pursuant to this Contract shall be in compliance with federal and state law and regulations and City Requirements. Developer shall obtain all permits and approvals required to do the work authorized under this Contract.

  • Applicable Permits Written confirmation that all Applicable Permits then required are in full force and effect including a list of such clearances.

  • Compliance; Permits; Restrictions (a) The Company and each of its Subsidiaries are, and since January 1, 2019 have been, in compliance in all material respects with all applicable Laws, including the Federal Food, Drug, and Cosmetic Act (“FDCA”), the U.S. Food and Drug Administration (“FDA”) regulations adopted thereunder, the Public Health Service Act and any other similar Law administered or promulgated by the FDA or other comparable Governmental Body responsible for regulation of the development, clinical testing, manufacturing, sale, marketing, distribution and importation or exportation of drug and biopharmaceutical products (each, a “Drug Regulatory Agency”), except for any noncompliance, either individually or in the aggregate, which would not be material to the Company. No investigation, claim, suit, proceeding, audit or other action by any Governmental Body is pending or, to the Company’s Knowledge, threatened against the Company or any of its Subsidiaries. There is no agreement, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of material property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on the Company’s ability to comply with or perform any covenant or obligation under this Agreement, or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. Notwithstanding the foregoing, for all purposes of this Agreement, the Company does not make any representation or warranty (pursuant to this Section 2.15 or elsewhere) regarding the effect of any applicable Antitrust Laws on the Company’s ability to execute, deliver or perform its obligations under this Agreement or to consummate the Contemplated Transactions as a result of any enactment, promulgation, application or threatened or actual judicial or administrative investigation or litigation under, or enforcement of, any Antitrust Laws with respect to the consummation of the Contemplated Transactions. (b) The Company and its Subsidiaries hold all required Governmental Authorizations which are material to the operation of the business of the Company and its Subsidiaries as currently conducted (the “Company Permits”). Section 2.15(b) of the Company Disclosure Schedule identifies each Company Permit. The Company and its Subsidiaries hold all right, title and interest in and to all Company Permits free and clear of any Encumbrance. The Company and each of its Subsidiaries is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Company’s Knowledge, threatened, which seeks to revoke, limit, suspend, or materially modify any Company Permit. The rights and benefits of each Company Permit will be available to the Surviving Corporation or its Subsidiaries, as applicable, immediately after the Effective Time on terms substantially identical to those enjoyed by the Company and its Subsidiaries as of the date of this Agreement and immediately prior to the Effective Time. (c) There are no proceedings pending or, to the Company’s Knowledge, threatened with respect to an alleged material violation by the Company or any of its Subsidiaries of the FDCA, FDA regulations adopted thereunder, the Public Health Service Act or any other similar Law administered or promulgated by any Drug Regulatory Agency. The Company is not currently conducting or addressing, and to the Company’s Knowledge there is no basis to expect that it will be required to conduct or address, any corrective actions, including, without limitation, product recalls or clinical holds. (d) To the Company’s Knowledge, all clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company or its Subsidiaries, or in which the Company or its Subsidiaries or their respective current products or product candidates have participated, were and, if still pending, are being conducted in all material respects in accordance with standard medical and scientific research procedures and in compliance in all material respects with the applicable regulations of any applicable Drug Regulatory Agency and other applicable Law, including 21 C.F.R. Parts 50, 54, 56, 58 and 312. Since January 1, 2019, neither the Company nor any of its Subsidiaries has received any notices, correspondence, or other communications from any Drug Regulatory Agency requiring, or, to the Company’s Knowledge, threatening to initiate, the termination or suspension of any clinical studies conducted by or on behalf of, or sponsored by, the Company or any of its Subsidiaries or in which the Company or any of its Subsidiaries or their respective current products or product candidates have participated. (e) Neither the Company nor any of its Subsidiaries is the subject of any pending or, to the Company’s Knowledge, threatened investigation in respect of its business or products by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto. To the Company’s Knowledge, neither the Company nor any of its Subsidiaries has committed any acts, made any statement, or failed to make any statement, in each case in respect of its business or products that would violate the FDA’s “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy, and any amendments thereto. None of the Company, any of its Subsidiaries or any of their respective officers, employees or agents has been convicted of any crime or engaged in any conduct that could result in a debarment or exclusion (i) under 21 U.S.C. Section 335a or (ii) any similar applicable Law. No debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or, to the Company’s Knowledge, threatened against the Company, any of its Subsidiaries or any of their respective officers, employees or agents.